Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Accumulated evidence indicates that cannabidiol (CBD), a nonpsychotomimetic and nonaddictive main component of the Cannabis sativa plant, reverses anxiety-like behaviour. The purpose of the present study was to assess the efficacy of CBD treatment for Japanese late teenagers with social anxiety disorder (SAD). Thirty-seven 18 - 19 years old Japanese teenagers with SAD and avoidant personality disorder receive, in a double-blind study, cannabis oil (n = 17) containing 300 mg CBD or placebo (n = 20) daily during 4 weeks. SAD symptoms were measured at the beginning and end of the treatment period using the Fear of Negative Evaluation Questionnaire and the Liebowitz Social Anxiety Scale. CBD significantly decrease anxiety measured by both scales. The results indicate that CBD could be a useful option to treat social anxiety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Measurement of social-evaluative anxiety.
Watson, D., & Friend, R. (1969) · Journal of Consulting and Clinical Psychology · doi:10.1037/h0027806 · Cited by 3,467 · cited 3×
“This measure uses a true-false scale and is known to show good internal consistency and test-retest reliability (Watson and Friend, 1969).”
MethodLiebowitz, M. R. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000414022 · Cited by 2,266
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
Merikangas, K. R., He, J.-P., Burstein, M., Swendsen, J., Avenevoli, S., Case, B., Georgiades, K., Heaton, L., Swanson, S., & Olfson, M. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.10.006 · Cited by 1,579 · cited 2×
“A survey conducted in the United States showed that the disorder starts as early as age 5 and peaks around age 12 (Merikangas et al., 2011).”
BackgroundInfluentialBrown, T. A., Campbell, L. A., Lehman, C. L., Grisham, J. R., & Mancill, R. B. (2001) · Journal of Abnormal Psychology · doi:10.1037//0021-843x.110.4.585 · Cited by 1,562
Stein, M. B., & Stein, D. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60488-2 · Cited by 1,137
Prevalence and incidence studies of anxiety disorders: A systematic review of the literature
Somers, J. M., Goldner, E. M., Waraich, P., & Hsu, L. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100206 · Cited by 1,114
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Miller, I., Flamini, R., Wilfong, A., Filloux, F., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00379-8 · Cited by 900
Brown, T. A., Di Nardo, P. A., Lehman, C. L., & Campbell, L. A. (2001) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.110.1.49 · Cited by 887
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771
Craske, M. G., Stein, M. B., Eley, T. C., Milad, M. R., Holmes, A., Rapee, R. M., & Wittchen, H.-U. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.24 · Cited by 652
McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., Taylor, A., & Wright, S. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17030325 · Cited by 617
Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379283 · Cited by 535 · cited 1×
“A pioneering study that investigated the effects on SAD patients showed that CBD reduces anticipatory anxiety (Crippa et al., 2011).”
BackgroundCosta, B., Trovato, A. E., Comelli, F., Giagnoni, G., & Colleoni, M. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.006 · Cited by 395
Effects of ipsapirone and cannabidiol on human experimental anxiety
Zuardi, A. W., Cosme, R. A., Graeff, F. G., & Guimarães, F. S. (1993) · Journal of Psychopharmacology · doi:10.1177/026988119300700112 · Cited by 364
Research works printed but not linked: 13
- 2000, Diagnostic and statistical manual of mental disorders. 4th Edn, 1
- Blessing, 2015, Cannabidiol as a potential treatment for anxiety disorders, Neurotherapeutics, 12, 825, 10.1007/s13311-015-0387-1 · DOI · Paper page
- De Gregorio, 2019, Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain, Pain, 160, 136, 10.1097/j.pain.0000000000001386 · DOI · Paper page
- Di Nardo, 1994, Anxiety disorders interview schedule for DSM-IV (ADIS-IV), 1
- First, 1997, User’s guide for the structured clinical interview for DSM-IV Axis II personality disorders (SCD-II), 1
- Masataka, 2003, The onset of language, 1, 10.1017/CBO9780511489754 · DOI · Paper page
- Nordahl, 2016, Paraxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: a randomized clinical trial, Psychother. Psychosom., 85, 346, 10.1159/000447013 · DOI · Paper page
- Ogino, 2004, Managing categorization and social withdrawal in Japan: rehabilitation process in a private support group for hikikomorians, Int. J. Soc. Psychiatry, 13, 120, 10.1111/j.1475-6781.2004.00057.x · DOI · Paper page
- Parker, 2006, Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: an animal model of anticipatory nausea and vomiting, Physiol. Behav., 87, 66, 10.1016/j.physbeh.2005.08.045 · DOI
- Ryan, 2012, Treating adolescents with social anxiety disorders in schools, Child Adolesc. Psychiatr. Clin. N. Am., 21, 1050118, 10.1016/j.chc.2011.08.011 · DOI · Paper page
- Saito, 2007, Why hikikomori is cured?, 1
- Scuderi, 2009, Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders, Psychother. Res., 23, 597, 10.1002/ptr.2625 · DOI · Paper page
- Teo, 2010, A new form of social withdrawal in Japan: a review of Hikikomori, Int. J. Soc. Psychiatry, 56, 175, 10.1177/0020764008100629 · DOI · Paper page
Cited by
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
Han, K., Wang, J.-Y., Wang, P.-Y., & Peng, Y.-C.-H. (2024) · Psychiatry research · doi:10.1016/j.psychres.2024.116049 · Cited by 54
Biopsychosocial model social anxiety and substance use revised
Buckner, J. D., Morris, P. E., Abarno, C. N., Glover, N. I., & Lewis, E. M. (2021) · Current Psychiatry Reports · doi:10.1007/s11920-021-01249-5 · Cited by 52
Pharmacotherapy for Anxiety Disorders.
O’Leary, K. B., & Khan, J. S. (2024) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2024.04.012 · Cited by 22
Metadata
- Authors
- Masataka, N.
- Venue
- Frontiers in Psychology
- Publisher
- Frontiers Media SA
- Published
- 2019-11-08
- Volume
- 10
- Pages
- 2466-2466
- ISSN
- 1664-1078 (ISSN-L)
- OpenAlex
- W2981783294
- Cited by
- 192
- References
- 16
- FWCI
- 11.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.